Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report
R L Piekarz, R Robey, V Sandor, S Bakke, W H Wilson, L Dahmoush, D M Kingma, M L Turner, R Altemus, S E Bates, R L Piekarz, R Robey, V Sandor, S Bakke, W H Wilson, L Dahmoush, D M Kingma, M L Turner, R Altemus, S E Bates
Abstract
Depsipeptide, FR901228, has demonstrated potent in vitro and in vivo cytotoxic activity against murine and human tumor cell lines. In the laboratory, it has been shown to be a histone deacetylase (HDAC) inhibitor. In a phase I trial of depsipeptide conducted at the National Cancer Institute, 3 patients with cutaneous T-cell lymphoma had a partial response, and 1 patient with peripheral T-cell lymphoma, unspecified, had a complete response. Sézary cells isolated from patients after treatment had increased histone acetylation. These results suggest that inhibition of HDAC is a novel and potentially effective therapy for patients with T-cell lymphoma.
Source: PubMed